MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)

Abstract Background Doublet chemotherapy in combination with a biologic agent has been a standard of care in patients with metastatic colorectal cancer for over a decade. The evidence for a “lighter” treatment approach is limited to mono-chemotherapy plus bevacizumab in the RAS unselected population...

Full description

Bibliographic Details
Main Authors: Ho Wai Derrick Siu, Niall Tebbutt, Lorraine Chantrill, Chris Karapetis, Christopher Steer, Kate Wilson, David Espinoza, Lisa Bailey, Sonia Yip, Jeff Cuff, Nick Pavlakis, Subotheni Thavaneswaran, Karen Briscoe, Ratnesh Srivastav, Jennifer Shannon, Eva Segelov, Jeannie Tie, Susan Caird, Alessandra Francesconi, Timothy Price, Melanie Wuttke, Rahul Ladwa, Katrin Sjoquist, Matthew Burge
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Cancer
Subjects:
Metastatic colorectal cancer
Elderly
Older adults
RAS
BRAF
Panitumumab
Online Access:https://doi.org/10.1186/s12885-021-08644-4

Internet

https://doi.org/10.1186/s12885-021-08644-4

Similar Items